In June 2018, the FDA announced the approval of Epidiolex, a CBD-based drug, as a Schedule Class V substance under the Controlled Substance Act. Its adaptation came three months after it has been approved as a treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome, two rare and extremely serious forms of epilepsy1.
GW Pharmaceuticals CEO, Justin Gover said, “We are pleased that the DEA has placed Epidiolex in the lowest restriction Schedule, because it will help ensure that patients with LGS and Dravet syndrome, two of the most debilitating forms of epilepsy, can access this important new treatment option through their physicians. With this final step in the regulatory process completed, we are working hard to make Epidiolex available within the next six weeks as we know there is excitement for a standardized version of cannabidiol that has undergone the rigor of controlled clinical trials and been approved by the FDA2“.